NCT04664829CompletedPhase 1
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Source: ClinicalTrials.gov · Last updated 23 Sept 2025
Brief summary (registry, in English)
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 9 Nov 2020
- Start date
- 1 Oct 2020
- Primary completion date
- 4 Aug 2025
- Lead sponsor
- National Cancer Centre, Singapore
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT04664829
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- From 1 Oct 2020 to the primary completion date, 4 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous palliative radiotherapy to potentially biopsy-able lesion
- Spinal cord compression not definitively treated with surgery and/or radiation
Other
- Active symptomatic central nervous system (CNS) metastases
- Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
Who the study is looking for
- Patients with histologically or cytologically proven metastatic TNBC
- Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
- Females aged 21 years and older
- ECOG performance status 0 or 1
- Life expectancy greater than three months
- Patients have normal organ and marrow function
- Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
Age in the registry: 21 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center Singapore Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.